New hope for pancreatic cancer: targeted drug combo enters final trial phase
NCT ID NCT07079228
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 3 trial is testing whether adding an experimental drug called QLS31905 to standard chemotherapy helps people with advanced pancreatic cancer live longer. The study includes 602 adults whose tumors have a specific marker (CLDN18.2). Participants are randomly assigned to receive either QLS31905 or a placebo, both combined with chemotherapy. The main goal is to see if the drug improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS31905 (an experimental drug) plus chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to
If it works, this could provide a new first-line treatment option for people with a specific type of advanced pancreatic cancer, potentially extending survival.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The drug may not improve survival or could cause side effects like infusion reactions or increased toxicity from chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••